Contents
Section 1 Infectious diseases
1. Approach to fever in ICU
2. New criteria for defining sepsis and septic shock, new methods for rapid diagnosis
3. Discuss modern updates of SSCG-2021
4. Give rationale approach to fluid therapy in septic shock (2021)
5. Dilemma and new concept of fluid therapy in septic shock
6. Resuscitation goals and additional end points in patients with septic shock
7. New concept of vasopressor& inotropes therapy in septic shock
8. Rationale for early Nor Epinephrine in septic shock
9. Antibiotic stewardship
10. Value of antibiotic stewardship programs (ASPs)
11. Antibiotic de-escalation.
12. Short versus long duration of antibiotics for VAP.
13. Optimization of antimicrobial therapy in ICU acquired infections
14. TTT of severe gram- positive infections.
15. A. baumannii
16. Early recognition & Management of invasive (systemic) candidiasis in the critically ill
17. Systemic fungemia
18. Diagnosis and management of aspergillosis (IDSA 2016 guidelines summary)
19. Necrotizing fasciitis (NF)
20. Toxic shock syndrome (TSS)
21. Immunomodulation in critically ill patients
22. Plasmapheresis vs immunoglobulin in ICU
23. Blood purification in sepsis and AKI in critically ill patients
24. Use of steroid in septic shock controversy
25. Sepsis associated liver dysfunction (SALD)
26. Microcirculatory dysfunction in systemic sepsis
27. Macrophage activating syndrome
28. Liberal Vs restrictive transfusion in septic shock controversy
29. Isolation precautions
30. [Link] in ICU
31. EGDT in septic shock
32. Novel biomarkers of sepsis
33. Role of TLRs in development of sepsis
34. Acute endothelial dysfunction and sepsis
35. Vasopressin as adjunct to NE in septic shock
36. Thiamine as a metabolic resuscitator in septic shock
37. Different methods of Immunomodulation in sepsis
38. IVIG controversy in sepsis
39. VHVHF
40. Microbiota & MBT
41. Neuroendocrinal axis in inflammation & sepsis
42. Antimicrobial peptides and its potential application in sepsis
43. Metagenomic sequencing in ICU
Section 2 Fluid therapy
44. Fluid responsiveness (FR) & functional hemodynamic parameters (FHP)
45. Focused clinical hemodynamic assessment in septic shock
46. POCUS as a new concept in assessment of fluid status in hypo and hypervolemic
patients
47. Doppler technology in detection and management of congested patients
48. US in hemodynamic management
49. Liberal Vs restrictive chloride IVFs in critically ill patients
50. Colloid therapy
51. Effect of volume replacement
52. Value of pCO2 gap
1
53. Value of Scvo2
Section 3 Endocrine and metabolic system
54. Best use of Corticosteroid in critically ill patients
55. New guidelines addressing hyponatremia (2014)
56. SIADH
57. Hyponatremia in SAH.
58. Principles of management of hypernatremia
59. Hypercalcemia
60. Hyperkalemia due to reduced urinary potassium excretion
61. Phosphate and magnesium disorders
62. Acute metabolic acidosis
63. Bicarbonate therapy in lactic acidosis
64. Endocrine emergencies
65. Adrenal gland dysfunction in critical illness/critical illness‑related corticosteroid
insufficiency (CIRCI)
66. Differential diagnosis of Adrenal / Addisonian crisis
67. Diabetes insipidus
68. Thyroid storm
69. Non-thyroidal illness syndrome (NTIS) aKa lowT3 syndrome or euthyroid sick
syndrome (ESS)
70. Recent updates in management of diabetes and optimal glycemic control in CIPs
71. Value of lactate in critically ill patients
72. Myths and facts about lactate
73. Lactate and the brain
74. Lactate and acute heart failure syndrome
75. Strong ion difference SID aKa (Stewart approach) or physicochemical approach
76. Effects of Glucocorticoids (GCs)
77. Permissive hyperglycemia
78. Haldane effect VS Bohr effect
79. Clinical implications of ANP in ICU
80. Vasopressin
81. Role of RAAS modulation in CVS and pulmonary system
82. Platelet function beyond hemostasis.
Section 4 Renal system
83. RRT
84. Pros &cons of early RRT
85. Initiation strategies for RRT in AKI controversies
86. CRRT Vs IHD in AKI
87. Drug induced AKI and preventive strategies
88. Rhabdomyolysis
89. Canadian Association of Radiologists Guidance on CA- AKI
90. CSA-AKI
91. Acute kidney syndrome (AKS)
92. Controversies of fluids in AKI
93. Furosemide stress test (FST)
94. Value of urine examination including urine electrolytes in diagnosis of AKI.
95. Novel Biomarkers of AKI
96. Dosing and quantification of RRT in AKI
97. Kidney brain cross talk
98. Sepsis & AKI crosstalk
99. Role of leucocytes in pathogenesis of AKI
Section 5 Cardiovascular system
100. Management of NSTE-ACS (ESC 2020)
101. ACS ESC 2023
102. Troponitis
2
103. Facilitated versus primary PCI in STEMI
104. Merits and pitfalls of noninvasive studies of myocardial ischemia
105. Pros and Cons of DAPT after ACS in patients undergoing PCI
106. Acute heart failure (AHF)
107. Anemia in heart failure
108. Acute myocarditis
109. Acute presentation of prosthetic valve dysfunction
110. Refractory septic shock
111. RV dysfunction & fluid administration
112. Sepsis induced myocardial dysfunction (SIMD)
113. Septic cardiomyopathy
114. Takotsubo cardiomyopathy (TCM)
115. Cardiorenal syndrome
116. CRS type 1 or acute CRS (CRS-1)
117. Management of AF. (ESC 2020)
118. AF with diabetes ESC 2023
119. AF with (stroke and post operative) ESC 2024
120. Diagnostic algorithm for high-risk PE with or without hemodynamic instability
121. Diagnostic modalities of PE
122. Advanced Management of intermediate - high risk PE
123. Life threatening tachyarrhythmias
124. Long QT syndrome (LQTS)
125. WCT
126. Electrical storm
127. Sudden cardiac death (SCD)
128. Anti-arrhythmic toxicity in ICU
129. New guidelines in CPR
130. Non-bradycardia indications of cardiac pacing
131. Cardiac tamponade
132. Leaky (ruptured) AAA
133. Non pharmacological management of severe refractory heart failure
134. Blue toe syndrome (BTS)
135. Infectious aortitis according to most recent guidelines.
136. Management of cardiovascular disease risk and kidney failure in patients with CKD
and DM
137. Timing of surgery after stroke, post-operative complications (ESC infective
endocarditis 2023)
138. Cardiac output monitoring devices
139. AF&CHF
140. Tachycardia-induced cardiomyopathy (TCMP)
141. Novel antifailure drugs
142. Novel inotropes
143. Novel biomarkers of ACS
144. Neurologically mediated cardiopulmonary disorders
145. Levosimendan in refractory heart failure
146. Role of calcium sensitizer (levosimendan) in cardiovascular therapy
147. Role of neprilysin inhibitors in refractory heart failure
148. Role of beta blocker therapy in acute myocardial infarction
149. Role of biomarkers as a prognostic indicator for patients with HF
150. Utility of Inflammatory Biomarkers for Predicting Organ Failure and Outcomes in
Cardiac Arrest Patients
151. Role of angiotensin in critical care
152. Pros and cons of epinephrine in cardiac arrest
153. Epinephrine versus vasopressin in cardiac arrest
154. Acute cardiovascular events in prediabetic
155. Bedside microcirculatory assessment as a key requirement in ICU
156. CULPRIT -SHOCK trial
157. Pathobiology of coronary artery narrowing
158. p MCS.
3
159. Durable MCS
160. IABP Vs ECMO in cardiogenic shock
161. Prevalence of major bleeding in pMCS
162. CPR in adults with MCS
Section 6 ECMO
163. Indications and contraindications of VV- ECMO and VA -ECMO
164. Role of ECMO
165. Modes of ECMO
166. ECMO configuration
167. Components of ECMO circuit
168. [Link] initiation / commencement
169. Settings
170. Anticoagulation
171. Medications and ECMO
172. Gas exchange management
173. Investigations required for patients on ECMO
174. Preventing Complications
175. MV setting during VV/VA- ECMO
176. Monitoring during VV/VA- ECMO
177. When to wean V-V ECMO?
178. How to wean V-V ECMO?
179. How to do decannulation of V-V ECMO?
180. When to wean V-A ECMO?
181. How to wean V-A ECMO?
182. How to do decannulation of V-AECMO?
183. Rush (emergency) weaning
184. Pros and cons different types of ECMO
185. Complications during ECMO
186. Survival prediction scores
187. Evidence
188. Impact of ECMO on PK/PD
189. Recent trends in ECMO
190. Recent trends concerning antimicrobial regimens & dosing in ECMO
191. To prone or not to prone ARDS patients on ECMO
Section 7 Respiratory system
192. Necrotizing pneumonia
193. Pneumonia in an immunocompromised patient
194. Serious epidemic viral pneumonia
195. SARS
196. Viral pneumonia
197. Silent aspiration
198. Refractory hypoxemia
199. 199. ARDS and CARDS
200. Algorithm for T2RF with normal airways
201. Pros &Cons of aerosolized antibiotics
202. Acute respiratory failure in elderly
203. Life threatening acute asthma & Refractory bronchial asthma
204. Asthma management guidelines (NAEPP 2020&GINA 2022)
205. Factors affecting P(a-A) O2 gradient in ARDS
206. Pulmonary complications of acute CVA
207. Pulmonary complications of liver cirrhosis
208. Pulmonary hypertension (PH)
209. Respiratory management in patients with severe brain injury
210. Acute presentation of bronchial cancer
211. Acute chest syndrome
212. Dyspnea on MV
213. Main concept of pathophysiologic mechanisms leading to hypoxemia in ARDS
4
214. ARDS biomarkers
215. ARDS sub phenotypes.
216. Pros and cons of assisted MV in ALI.
217. Pros and Cons of non-conventional modes in ARDS
218. Opening pressures and atelectatrauma
219. Manipulation of lung perfusion
220. Bedside monitoring of lung mechanics in ARDS
221. Therapeutic implications of permissive hypercapnia in sepsis & ALI
222. VILI & mechanically ventilated spontaneously breathing patients
223. VV ECMO Vs MV in ARDS management
224. Endo bronchial valve
Section 8 Mechanical ventilation
225. Intubation bundle care management
226. Complication of MV and how to prevent
227. VAE (New concepts and Studies)
228. How to Minimize the risk of VILI
229. Acute hypoxemia on ventilator / Respiratory distress in MV patients
230. Automated modes of MV
231. Closed loop ventilation
232. Role of intelligent ventilation in ICU
233. Sedation and analgesia in MV patients / Sedation strategies in critically ill patients
234. Early goal directed sedation (EGDS) in mechanical ventilation
235. Impact of sedation and analgesia recent protocol on MV patients’ outcome
236. Prone ventilation
237. Effect of PP on respiratory/lung mechanics &gas exchange in ARDS patients
238. Effect of RMs on lung mechanics and gas exchange
239. Effects of RMs on respiratory mechanics and gas exchange.
240. Weaning failure
241. Recent trends in weaning protocols in MV
242. Recent strategies in ventilator asynchrony management
243. NIV in acute respiratory failure
244. High flow nasal cannula (HFNC)
245. HFNC benefits oxygenation and beyond oxygenation.
Section 9 COVID-19
246. Complications of COVID-19.
247. Respiratory failure (ARDS) management
248. Coagulopathy.
249. Cardiovascular complications of COVID-19.
250. Modified CPR in COVID-19
251. Immunomodulatory therapies for COVID-19
Section 10 Nervous system
252. Stroke in AF patients (assessment and management)
253. Cryptogenic stroke
254. Modern concepts in management of AIS
255. NOACs replacing warfarin for stroke prevention in AF
256. SAH management
257. Posterior reversible encephalopathy syndrome (PRES)
258. Metabolic encephalopathy (seizures)
259. Psychological problems impacted on ICU patients
260. Tetany
261. Transient paralysis
262. Management of recent neck rigidity
263. Brain death criteria
264. Confounding factors that interfere with brain death evaluation
5
265. Pathophysiological consequences of brain death on Cardiovascular, respiratory and
endocrine systems.
266. Post cardiac arrest syndrome
267. Assessing and improving neurologic outcome after CPR, Post resuscitation care
268. Critical care management of brain-dead organ donor
269. Effect of s/p CPR, MH, and SAH on cerebral circulation& Neurological outcome
270. Therapeutic hypothermia after cardiac arrest
271. Role of therapeutic hypothermia after cardiac arrest
272. Therapeutic hypothermia / Targeted temperature management
273. 273. Therapeutic hypothermia
274. Cerebral edema.
275. Mannitol vs hypertonic saline (HS) in treatment of raised ICP , Give an account on
osmotherapy.
276. Hypertonic saline (HS) in critical
277. Treatment of raised ICP after TBI
278. Propofol vs midazolam in TBI
279. Neuromonitoring
280. Applications of neuromonitoring in non-brain injured patient
281. Brain–Multiorgan Cross-Talk in Critically Ill Patients with Acute Brain Injury
282. Gut brain cross talk
283. Brain biomarkers after cardiac arrest as a predictor of outcome
284. Acute brain injury and acute endothelial dysfunction
285. Normoxia and hyperoxia in neuroprotection
286. NO inhalation in stoke / ischemic brain injury
Section 11 Gastrointestinal system
287. Pathophysiology & clinical features of FHF
288. Fulminant hepatic failure (FHF)
289. Stress ulcer
290. Acute GI bleeding (diagnostic evaluation) 2024 guidelines
291. Acute pancreatitis
292. Acute pancreatitis
293. Acute mesenteric ischemia
294. Toxic megacolon
295. Abdominal compartment syndrome
296. ICU diarrhea
297. GIT motility disorders in CIPs
298. Hepato renal syndrome (HRS)
299. Hepatopulmonary syndrome (HPS)
300. Liver decompensation during septic episode (EASL 2018)
301. Autoimmune hepatitis (AIH)
302. Contraindications to liver transplantation
303. Infections in liver transplant patients
304. Post operative care of liver transplant
305. Mechanisms of ascites and it’s complications
306. Acute on chronic liver failure (ACLF)
307. Extra corporeal liver support
308. Indications of pancreas transplantation according to ADA
Section 12 Hematology and oncology
309. Thrombotic Thrombocytopenic Syndrome (TTS)
310. Value of thrombocytopenia in critically ill patients
311. NOACS
312. Resuming anticoagulation after a hemorrhagic event.
313. Transfusion related pulmonary complications
314. Diagnostic criteria and clinical manifestation of CAPS
315. Indications and outcomes of plasmapheresis in critical care setting
316. Hemoglobinopathies & hemolytic crises
317. Viscoelastic hemostatic assays (VHA) guided therapy
6
318. Viscoelastic Hemostatic Assays (VHAs)
319. ICU presentations of para malignant/neoplastic syndrome
320. Tumor lysis syndrome (TLS)
Section 13 Trauma and burn
321. Trauma associated coagulopathy
322. Updates of traumatic acute SCI
323. Burn wound sepsis
324. Acute Radiation Syndrome - K19
325. Role of critical care in management of major nuclear disaster
326. Acute compartment syndrome
Section 14 Perioperative care
327. Peri operative cardiac events in non-cardiac surgical patient
328. Perioperative management of obese diabetic patient
329. Post-operative management of bariatric surgery
330. Post operative hypoxia (POH)
Section 15 Nutrition
331. Malnutrition in ICU
332. Malnutrition assessment (ESPEN 2018)
333. Energy Goals in the Critically Ill Adult
334. Calculation of nutritional requirements
335. Enteral nutrition in critically ill patient (ASPEN 2016)
336. Consequences of overfeeding and underfeeding in critically ill patients
337. Refeeding syndrome (RFS)
338. Wernicke- Korsakoff syndrome (WKS)
339. Micronutrients (MN) and critically ill patients
340. Value of indirect calorimetry (IC)
Section 16 Obstetrics
341. HTN in pregnancy (ESC 2018)
342. Hyperemesis gravidarum (HEG) complicated by wernicke’s encephalopathy (WE)
343. Respiratory failure in pregnancy
344. ARDS in pregnancy
345. Acute fatty liver of pregnancy (AFLP)
Section 17 Toxicology
346. Toxidromes
347. Street drugs
348. Aluminum phosphide poisoning
Section 18 General issues
349. Burn out syndrome (BOS)
350. DDX of anaphylaxis in ICU
351. DDX of hyperthermia
352. Decompression sickness (DCS)
353. DPL Indications and interpretations
354. Early mobilization on patients
355. Effect of noise on critically ill patients
356. Effect of pain on critically ill patients
357. Heat stroke
358. Hypoalbuminemia and albumin repletion in
359. Malignant hyperthermia
360. MODS
361. Organ dysfunction score
362. Post-intensive care syndrome (PICS)
7
363. Post-intensive care syndrome (PICS)
364. Pros & cons of long-distance transport of ventilated patients
365. SLE in ICU
366. Skin failure
367. Cytokine storm (cytokine release syndrome)
368. Hemophagocytic lymphohistocytosis (HLH)
369. Immunomodulating nutrients controversy in ICU
370. Growth hormone controversy in critically ill
371. Importance Microvesicles in the systemic regulation of hemostasis
372. Value of data management